Gastrointestinal tumours, colorectal


Tumour mutation profiles and Circulating tumour cells in Metastatic Colorectal Cancer patients treated with FOLFIRI + cetuximab: A Prospective Ancillary Study of the UNICANCER PRODIGE-28 trial

Blons, et al.


This exploratory analysis suggests that patients with any tumour mutation in MAPK pathway genes are not good candidates for maintenance treatment with cetuximab or treatment interruption after first-line FOLFIRI-cetuximab.



Tumor budding, a important prognostic factor in stage III colon cancer patients treated with oxaliplatin-based chemotherapy

Basile, et al.


In this large series from a randomized phase III trial, TB is an independent prognostic factor for OS and DFS in stage III CC patients treated with oxaliplatin-based standard adjuvant therapy. TB, adopted in the UICC TNM classification, should now be mandatory in every pathology report concerning patients resected from a stage III CC.



Risk of bowel obstruction in patients undergoing neoadjuvant chemotherapy for high-risk colon cancer: A nested case-control matched analysis of an international, multi-centre, randomised controlled trial (FOxTROT)

Glasbey, et al.


Safe selection for NAC for colon cancer can be informed by using two features that are available before treatment initiation and identify a small number of patients with high risk of preoperative obstruction.



Colorectal (CRC) cancer screening and diagnosis during the COVID-19 pandemic in Quebec – Canada

Tehfe, et al.


The COVID-19 affected screening and lead to decreased CRC diagnosis rate. Even with the recovery to pre-pandemic activities, catching up with the delays is a challenge for health authorities. The impact of the offloading of diagnostic and surgical activities on cancer mortality is hard to be estimated but is likely to be significant.



Impact of diabetes and metformin use on recurrence and outcome in early colon cancer (CC) patients – a pooled analysis of 3 adjuvant trials

E.S. Bergen, et al.


CC patients with diabetes type 2 had a significantly worse survival as well as shorter TTR. Furthermore, our data suggest that metformin may attenuate the detrimental effect of diabetes on CC patient outcomes.